Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABAT | P80404 | 2/20 | 0.55 |
| ▸ | OAT | P04181 | 1/20 | 0.50 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14175555 | 1.00 | ABAT (0.55) | ABATOATGABRR1 | |
| SCHEMBL14175553 | 1.00 | ABAT (0.55) | ABATOATGABRR1 | |
| SCHEMBL6855757 | 1.00 | ABAT (0.55) | ABATOATGABRR1 | |
| SCHEMBL22403908 | 0.81 | ABAT (0.50) | ABATOATGABRR1 | |
| SCHEMBL20049478 | 0.81 | ABAT (0.50) | ABATOATGABRR1 | |
| SCHEMBL17742867 | 0.80 | OAT (0.54) | ABATOATGABRR1 | |
| SCHEMBL17742866 | 0.80 | OAT (0.54) | ABATOATGABRR1 | |
| Cpp-115 Free Base SCHEMBL2407298 | 0.71 | ABAT (1.00) | ABATOATGABRR1 | |
| Cpp-115 Free Base SCHEMBL2408171 | 0.71 | ABAT (1.00) | ABATOATGABRR1 | |
| Cpp-115 Free Base SCHEMBL21404893 | 0.71 | ABAT (1.00) | ABATOATGABRR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6794413-B1 | Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase | NORTHWESTERN UNIVERSITY | 2004-09-21 | — | — | US | claimed |
| US-11207283-B2 | Inactivators of toxoplasma gondii ornithine aminotransferase for treating toxoplasmosis and malaria | NORTHWESTERN UNIVERSITY (US) | 2021-12-28 | — | — | US | disclosed |
| EP-3215144-B1 | ORNITHINE AMINOTRANSFERASE INHIBITION WITH GABA ANALOGUES FOR TREATMENT OF HEPATOCELLULAR CARCINOMA | UNIV NORTHWESTERN (US) | 2021-04-28 | — | — | EP | disclosed |
| US-10632088-B2 | Inactivators of Toxoplasma gondii ornithine aminotransferase for treating toxoplasmosis and malaria | NORTHWESTERN UNIVERSITY (US) | 2020-04-28 | — | — | US | disclosed |
| US-20180098952-A1 | INACTIVATORS OF TOXOPLASMA GONDII ORNITHINE AMINOTRANSFERASE FOR TREATING TOXOPLASMOSIS AND MALARIA | NORTHWESTERN UNIVERSITY (US) | 2018-04-12 | — | — | US | disclosed |
| US-9603820-B2 | Ornithine aminotransferase inhibition with GABA analogues for treatment of hepatocellular carcinoma | NORTHWESTERN UNIVERSITY (US) | 2017-03-28 | — | — | US | disclosed |
| US-9603820-B2 | Ornithine aminotransferase inhibition with GABA analogues for treatment of hepatocellular carcinoma | NORTHWESTERN UNIVERSITY (US) | 2017-03-28 | — | — | US | disclosed |
| US-20160128958-A1 | Ornithine Aminotransferase Inhibition with GABA Analogues for Treatment of Hepatocellular Carcinoma | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2016-05-12 | — | — | US | disclosed |
| US-20160128958-A1 | Ornithine Aminotransferase Inhibition with GABA Analogues for Treatment of Hepatocellular Carcinoma | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2016-05-12 | — | — | US | disclosed |
| US-8822539-B2 | Combination therapies: inhibitors of GABA transaminase and NKCC1 | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822539-B2 | Combination therapies: inhibitors of GABA transaminase and NKCC1 | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2014-09-02 | — | — | US | disclosed |
| WO-2011126733-A2 | COMBINATION THERAPIES: INHIBITORS OF GABA TRANSAMINASE AND NKCC1 | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2011-10-13 | — | — | WO | disclosed |
| US-20110237554-A1 | Combination therapies: inhibitors of GABA transaminase and NKCC1 | CHILDREN'S MEDICAL CENTER CORPORATION | 2011-09-29 | — | — | US | disclosed |
| US-20110237554-A1 | Combination therapies: inhibitors of GABA transaminase and NKCC1 | CHILDREN'S MEDICAL CENTER CORPORATION | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160128958-A1 | Ornithine Aminotransferase Inhibition with GABA Analogues for Treatment of Hepatocellular Carcinoma | OAT, OTC, ODC1 | ABAT 6/4885OAT 1/4885GABRR1 45/4885 |
| US-20180098952-A1 | INACTIVATORS OF TOXOPLASMA GONDII ORNITHINE AMINOTRANSFERASE FOR TREATING TOXOPLASMOSIS AND MALARIA | OAT, OTC, ABAT | ABAT 3/4885OAT 1/4885GABRR1 96/4885 |
| US-11207283-B2 | Inactivators of toxoplasma gondii ornithine aminotransferase for treating toxoplasmosis and malaria | OAT, OTC, ABAT | ABAT 3/4885OAT 1/4885GABRR1 96/4885 |
| US-20110237554-A1 | Combination therapies: inhibitors of GABA transaminase and NKCC1 | SLC6A1, SLC6A13, SLC6A11 | ABAT 31/4885OAT 88/4885GABRR1 41/4885 |
| US-10632088-B2 | Inactivators of Toxoplasma gondii ornithine aminotransferase for treating toxoplasmosis and malaria | OAT, OTC, ABAT | ABAT 3/4885OAT 1/4885GABRR1 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.